Table 2. Adjusted HRs of Death After Omicron Infection for Treatments and Confounding Variables.
| Variable | HR (95% CI) | |
|---|---|---|
| Nirmatrelvir (n = 62 324) | Molnupiravir (n = 44 662) | |
| Treatment | 0.16 (0.11-0.23) | 0.23 (0.16-0.34) |
| Age group, y | ||
| 50-64 | 3.87 (2.32-6.47) | 3.71 (2.32-5.94) |
| 65-74 | 6.31 (3.81-10.44) | 6.77 (4.29-10.69) |
| ≥75 y | 18.60 (11.49-30.13) | 18.35 (11.80-28.54) |
| Male sex | 1.80 (1.48-2.18) | 1.56 (1.33-1.83) |
| Race and ethnicity | ||
| Hispanic | 0.62 (0.34-1.15) | 0.60 (0.35-1.01) |
| Non-Hispanic Black | 0.60 (0.42-0.85) | 0.69 (0.53-0.89) |
| Other or unknowna | 1.43 (1.05-1.95) | 1.16 (0.85-1.57) |
| Ohio residency | 1.40 (1.05-1.87) | 1.45 (1.13-1.86) |
| SARS-CoV-2 immunity status | ||
| Vaccine boosters | 0.46 (0.38-0.56) | 0.55 (0.47-0.65) |
| Previously infected | 0.73 (0.51-1.06) | 0.76 (0.56-1.02) |
| Coexisting conditions | ||
| Respiratory | 1.19 (0.96-1.47) | 1.25 (1.05-1.48) |
| Immunocompromised | 4.60 (3.75-5.66) | 4.67 (3.95-5.53) |
| Cardiovascular system | 1.51 (1.16-1.96) | 1.55 (1.23-1.96) |
| Diabetes | 1.19 (0.96-1.48) | 1.25 (1.04-1.48) |
| Obesity | 1.14 (0.88-1.48) | 1.22 (1.00-1.50) |
| Other nonrespiratory | 3.31 (2.47-4.42) | 3.07 (2.36-4.00) |
| Socioeconomic index score | 3.57 (1.30-9.76) | 2.91 (1.27-6.68) |
| Date of COVID-19 diagnosis | ||
| June 22 to November 30, 2022 | 0.80 (0.63-1.01) | 0.84 (0.69-1.02) |
| December 1 to February 20, 2023 | 0.79 (0.59-1.06) | 0.79 (0.62-1.01) |
Abbreviation: HR, hazard ratio.
a
Other includes American Indian, Alaska Native, Asian, Native Hawaiian, Pacific Islander, and multiracial.